🟢 Outlook Therapeutics is trading 5.2% up today as it rebounds after-hours following FDA approval momentum

Outlook Therapeutics is trading at $1.12 (5.2% up) in after-hours trading, rebounding modestly from a sharp regular-session decline as investors digest the recent FDA approval of its wet AMD eye injection.

• The approval marks a major turning point for the company, ending a multi-year string of regulatory rejections and clearing the path for commercialization.
• Recent volatility reflects a market tug-of-war between the treatment's commercial potential and the company's current tight cash position.